Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Akebia Therapeutics's share price for the quarter that ended in Mar. 2026 was $1.39. Akebia Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 267.9 Mil. Therefore, Akebia Therapeutics's market cap for the quarter that ended in Mar. 2026 was $372.4 Mil.
Akebia Therapeutics's quarterly market cap
declined
from Sep. 2025 ($724.1 Mil) to Dec. 2025 ($427.3 Mil) and
declined
from Dec. 2025 ($427.3 Mil) to Mar. 2026 ($372.4 Mil).
Akebia Therapeutics's annual market cap
increased
from Dec. 2023 ($241.3 Mil) to Dec. 2024 ($427.2 Mil) and
increased
from Dec. 2024 ($427.2 Mil) to Dec. 2025 ($427.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Akebia Therapeutics's Enterprise Value for Today is $194.2 Mil.
Akebia Therapeutics (NAS:AKBA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Akebia Therapeutics Market Cap Related Terms
Akebia Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Akebia Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (AKBA) has a Market Cap of $305.8 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Akebia Therapeutics and its competitors. According to the industry distribution chart, Akebia Therapeutics ranks #465 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 45.6%.
Is Akebia Therapeutics' Market Cap too high?
Akebia Therapeutics' current Market Cap is $305.8 Mil. The Drug Manufacturers industry median Market Cap is 204.29. Akebia Therapeutics' value of $305.8 Mil is 49.7% above this industry median. Based on the distribution chart, Akebia Therapeutics ranks #465 out of 1020 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Market Cap compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #465 out of 1020 companies for Market Cap. This puts Akebia Therapeutics in the upper half of its industry. The industry median Market Cap is 204.29. Akebia Therapeutics' value of $305.8 Mil is 49.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 204.29, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Market Cap of $305.8 Mil is 49.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 204.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Market Cap is $305.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (AKBA) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.31, compared to a current price of $1.14 — trading 13% below its estimated fair value. The current Market Cap is $305.8 Mil and 49.7% above the Drug Manufacturers industry median of 204.29. Akebia Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Akebia Therapeutics (AKBA), the current Market Cap is $305.8 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (AKBA) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of $1.14 is trading 13% below its estimated GF Value™ of $1.31.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for AKBA:
Market Cap: $305.8 Mil
GF Value™: $1.31 vs. price of $1.14 (13% below fair value)
Industry Position: 49.7% above the Drug Manufacturers median (#465 of 1020)
No single metric tells the full story. See the AKBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
49GF Score
Get the complete analysis for AKBA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKBA has been successfully added to your 
